AMPAKINE Compound, CX717, Achieves Primary Endpoints In Second Phase IIa Respiratory Depression Study In Germany

Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in opioid-induced respiratory depression (RD) demonstrated that a single oral dose of 1500mg of the AMPAKINE® compound CX717 achieved statistical significance (p = 0.005) over placebo on the primary endpoint measure of spontaneous basal respiration without affecting opioid-induced analgesia.

More: continued here

Filed under: Depression on October 13th, 2008